Shanghai Pioneer Holding Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Steven Yang
Chief executive officer
CN¥752.0k
Total compensation
| CEO salary percentage | 83.0% |
| CEO tenure | 1.1yrs |
| CEO ownership | n/a |
| Management average tenure | 4yrs |
| Board average tenure | 2.4yrs |
Recent management updates
Recent updates
Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024
Apr 24
Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024
Apr 03Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 01Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks
Mar 22Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital
Feb 26Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?
Oct 21Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024
Sep 18Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024
Sep 01Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching
Aug 09Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 14Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 31Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly
Dec 15China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018
Sep 21China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Sep 02China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward
Jun 22China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064
Apr 14China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around
Jan 16These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely
Oct 11China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year
Sep 15China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056
Sep 01China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns
Aug 26Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture
May 22We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt
Apr 25Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?
Mar 14How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?
Feb 21
Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?
Feb 03Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?
Jan 16China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet
Dec 29Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?
Dec 14China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment
Nov 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | CN¥146m |
| Sep 30 2023 | n/a | n/a | CN¥168m |
| Jun 30 2023 | n/a | n/a | CN¥190m |
| Mar 31 2023 | n/a | n/a | CN¥213m |
| Dec 31 2022 | CN¥752k | CN¥624k | CN¥235m |
Compensation vs Market: Steven's total compensation ($USD103.89K) is below average for companies of similar size in the Hong Kong market ($USD330.03K).
Compensation vs Earnings: Insufficient data to compare Steven's compensation with company performance.
CEO
Steven Yang (35 yo)
1.1yrs
Tenure
CN¥752,000
Compensation
Mr. Yuewen Yang, also known as Steven, serves as Chief Executive Officer since April 2023 and serves as its Executive Director since September 16, 2022 and served as Chief Operating Officer at Shanghai Pio...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.3yrs | CN¥1.06m | 0.95% CN¥ 20.6m | |
| CEO & Executive Director | 1.1yrs | CN¥752.00k | no data | |
| Chief Financial Officer | 7.4yrs | no data | no data | |
| General Manager of Dental Business Division & Executive Director | 2.8yrs | no data | no data | |
| Company Secretary | 5.2yrs | no data | no data |
4.0yrs
Average Tenure
48yo
Average Age
Experienced Management: 1345's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.3yrs | CN¥1.06m | 0.95% CN¥ 20.6m | |
| CEO & Executive Director | 1.7yrs | CN¥752.00k | no data | |
| General Manager of Dental Business Division & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 2.4yrs | CN¥255.00k | no data | |
| Independent Non-Executive Director | 5.3yrs | no data | no data | |
| Non-Executive Director | 3.4yrs | CN¥173.00k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
2.4yrs
Average Tenure
59yo
Average Age
Experienced Board: 1345's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.